Health Condition 1: K760- Fatty (change of) liver, not elsewhere classified
Conditions
Interventions
Intervention1: Arq Biranjasif: 120ml/day (60ml BD) will be provided in two divided doses.
Control Intervention1: Arq Biranjasif: 120ml/day (60ml BD) will be provided in two divided doses.
Control Inte
Sponsors
National Institute of Unani Medicine
Eligibility
Inclusion criteria
Inclusion criteria: 1.Subjects of all gender, age of 19 to 75 years. 2.Diagnosed fatty liver disease on the basis of USG abdomen within one month or diagnosed during screening. 3.Either subjects with obesity (those who are not taking medication for obesity) or subjects with type-II diabetes mellitus or both. 4.Subjects willing to participate.
Exclusion criteria
Exclusion criteria: 1.Pregnancy or lactating mothers. 2.Subjects with hangover sickness. 3.Boozer subjects (alcohol consumption of more than 14 drinks per week (men) and more than 7drinks per week (women) 4.Subjects consuming hypolipidemic and anti- inflammatory drugs. 5.Subjects in any treatment known to affect hepatic function. 6.History of renal diseases, cardiovascular diseases, pulmonary diseases. 7.Subjects with total parenteral nutrition or bedridden subjects. 8.Subjects with protein malnutrition 9.Subjects with type 2 DM on insulin treatment. 10.Subjects with jejunoileal bypass surgery. 11.Patients on the following drugs and toxins - amiodarone, coralgil, tamoxifen, perhexiline maleate, corticosteroids, synthetic estrogens, methotrexate, iv tetracycline, highly active antiretroviral drugs (HAART).
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Improvement in investigational valuesTimepoint: Intervention Period 8 weeks, Enrollment period 1 year | — |
Secondary
| Measure | Time frame |
|---|---|
| Not ApplicableTimepoint: not Applicable | — |
Countries
India
Contacts
Public ContactDr C Raziya Thaseen
National Institute of Unani Medicine
Outcome results
None listed